Fundraising Fox
Boston · Seed–Growth · 45 people tracked
Also known as Polaris Growth Fund · POLARIS GROWTH MANAGEMENT, LLC
Not to be confused with Polaris Partners (Venture capital · Boston, US)
Find your way into Polaris Partners
Sign up to see every warm intro you have to Polaris Partners
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Polaris Partners team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Polaris Partners emphasizes real partnership as the foundation for building great companies. For nearly three decades, the firm has collaborated with talented biotech and healthcare entrepreneurs, backing transformational companies in these fields. Its approach centers on doing well by working together with founders throughout the company-building journey.
Source: firm website, verified Oct 13, 2026.
Team · 45 people
from the firm's website & curated & public directories
Jon Flint co-founded Polaris Partners with Steve Arnold and Terry McGuire in 1996. He began his venture career in 1984 at Burr, Egan, Deleage & Co., where he became a General Partner and helped build the firm's technology portfolio, having previously worked as a litigation associate at the Boston law firm Testa, Hurwitz and Thibeault and served on research teams for the Nixon Impeachment Inquiry Staff and the Watergate Special Prosecution Force. In 2005 he conceived of and co-founded Living Proof, and in 2015 he and Terry McGuire formed Polaris Founders Capital to invest their own capital across stages and sectors.
Alan Crane joined Polaris Partners in 2002 as an entrepreneur partner, focusing on building and investing in healthcare companies. He has held founder, CEO, and Chairman roles across ten Polaris companies, including co-founding Zag Bio, Seismic Therapeutic, and Dyno Therapeutics, and founding Pandion Therapeutics (acquired by Merck). He was previously president and CEO of Momenta Pharmaceuticals (acquired by J&J) and SVP of corporate development at Millennium Pharmaceuticals, and holds degrees from Harvard College, Harvard Graduate School of Arts & Sciences, and Harvard Business School.
Alexandra Cantley is a managing partner at Polaris Partners, which she joined in 2019, working from the New York office with a focus on early-stage biotech and healthcare investments. Before Polaris, she was part of the initial research team at Inzen Therapeutics and previously held a research fellowship at Vertex Pharmaceuticals. She holds a PhD in Chemical Biology from Harvard University and completed her undergraduate studies at New York University.
Amy Schulman is a managing partner at Polaris Partners focused on healthcare companies and early stage biotech startups. She joined the firm in 2014 and co-founded the Polaris Innovation Fund in 2017, which she continues to manage. Before Polaris she held roles at Pfizer including general counsel and president of Pfizer Nutrition and Pfizer Consumer Healthcare, was a partner at DLA Piper, and began her career at Cleary Gottlieb Steen & Hamilton; she is also a Senior Lecturer at Harvard Business School and holds degrees from Wesleyan University and Yale Law School.
Ellie McGuire is a managing partner in Polaris Partners' Boston office and manages the Polaris Innovation Fund, which she co-founded. Before Polaris, she was head of business development at Lyndra and held leadership and consulting roles in business development, operations, and strategy at life science companies including Arsia Therapeutics, SQZ Biotechnologies, and XTuit Pharmaceuticals. She also serves as an expert in residence for the Harvard Office of Technology Development.
Jonathan Ang joined Polaris Partners in 2023 as an entrepreneur partner in the firm's Singapore office, where he focuses on investing in, building, and scaling healthcare companies. Previously he was a Director on the Life Sciences Team at Temasek International in Singapore, managing its global healthcare services investment strategy and co-leading investments across multiple regions. He began his career on Cowen's Health Care Banking Team in New York and London, and holds an honors degree in Economics from The Wharton School of the University of Pennsylvania.
Brian Lewis joined Polaris in 2019 as director of legal and investment analytics in the firm's San Francisco office, where he handles investment analytics projects along with legal operations and deal matters. He previously worked at Latham & Watkins LLP, first as a senior paralegal and then as a quantitative analysis manager in the corporate department, supporting financial and capitalization modeling for equity financings, acquisitions, and IPOs. He holds a BS in Mathematics from UCLA, a paralegal certification from San Francisco State University, and an MBA from UC Berkeley's Haas School of Business.
Nil Gural is a principal at Polaris Partners, which she joined in 2022, where she works on biotech and healthcare investments. She previously was a manager in Bain & Company's healthcare practice covering pharma and medical devices, and earlier was part of the founding team at Glympse Bio, contributing to its platform technology. She holds a PhD from the Harvard-MIT HST program, where she was an HHMI fellow, and a BS in Biomedical Engineering from Washington University in St. Louis.
Paulina Hill combines institutional VC and angel investing—writing $100K–$250K biotech checks to access scientific founders early; a PhD molecular biologist who actively architects complex therapeutics like targeted protein degraders.
Amir Nashat is an entrepreneur partner at Polaris Partners in Boston, where he invests in healthcare companies and takes on executive roles inside portfolio companies. He joined the firm in 2002 and serves as a managing partner of Polaris Funds VI through IX. He has repeatedly stepped in as CEO of Polaris-backed startups, including Dewpoint Therapeutics, Jnana, Living Proof, Olivo Labs, Paratus Sciences, and Sun Catalytix, and is currently CEO of Souffle Therapeutics. He earned a doctorate in chemical engineering at MIT under Robert Langer and holds materials science and mechanical engineering degrees from UC Berkeley, and was named to the Forbes Midas List in 2016.
Brian Chee is a managing partner at Polaris Partners in San Francisco who invests in healthcare companies. He joined Polaris as an associate in Boston shortly after the firm's founding in 1996, and previously worked at Goldman Sachs in New York and San Francisco and at Baxter Healthcare, where he developed experience across medical devices, pharmaceuticals, and biotechnology. He holds a BS from the United States Military Academy at West Point and an MBA from the Tuck School of Business at Dartmouth College, and served as a Captain in the US Army Corps of Engineers.
Dave Barrett is a senior advisory partner in Polaris Partners' Boston office who focuses on healthcare technology. He joined Polaris in 2000 after an operating career that included serving as COO of Calico, SVP of worldwide operations at Pure Atria/Rational Software, and various leadership roles over 12 years at Lotus Development. He also serves as a managing partner of Polaris Funds VI-IX and the Polaris Healthcare Technology Opportunities Fund, with particular interest in AI and ML platforms for care management.
Elizabeth Dowd joined Polaris in 2018 as an executive assistant and office manager in the firm's Boston office. Before Polaris, she provided administrative support to various non-profits and worked as a tour guide at historic sites.
Gary Swart is an operating partner at Polaris Partners in San Francisco, where he invests in healthcare services and products. He previously served as CEO of oDesk (later Upwork), which merged with Elance, and earlier held roles as Chief Revenue Officer of Intellibank and a business unit executive at IBM following its acquisition of Rational Software. He also mentors at accelerators including Alchemist and StartX.
Harold Friedman serves as Chief Financial Officer at Polaris Partners. He has experience managing financial operations for venture capital and private equity firms with assets ranging from $200 million to $4.5 billion, and works with managing directors, limited partners, and external service providers.
JoAnne Trayers joined Polaris Partners in 2001 as executive assistant to co-founder Jon Flint on the technology side of the firm, and more recently moved to the healthcare team supporting Alan Crane. Before Polaris, she supported the CEO and CFO at Allaire Corporation, worked with the senior management team at Powersoft Corporation, and served as operations manager at FirstSense Software.
Kara Greenwood joined Polaris in 2023 as an executive assistant supporting the firm's New York office. She has worked as a c-suite executive assistant across various industries, with prior roles supporting executives at Goldman Sachs, SBE Entertainment, a private family office, and Virtue Labs. She holds a BS in Communications from The University of Tennessee Knoxville.
Kirti Anand joined Polaris in 2022 as fund controller, where she handles fund management and reporting. She previously worked as an Audit Senior Manager at BDO in the asset management group, focusing on alternative investments across venture capital and private equity clients. She is a Certified Public Accountant (Inactive) and holds a Master of Accounting degree from Golden Gate University.
Lauren Crockett is general counsel and chief compliance officer at Polaris Partners, which she joined in 2019, handling legal, compliance, and operational matters including fundraising, fund management, and deal structuring. She previously served as assistant general counsel at LendingClub Corporation and was a corporate associate at Latham & Watkins, and earlier held legal and government affairs roles at Bain Capital. She holds a JD from Harvard Law School and a BA in history from Dartmouth College.
Liz Wong joined Polaris Partners in 2025 as executive assistant and office manager for the firm's San Francisco office. She previously provided administrative and office management support to finance, advertising, and tech companies including FCB Global, Vantage Point Capital, and Intuit.
Maureen St. Pierre joined Polaris Partners in 2002 as a portfolio analyst supporting the finance and investor relations teams. Before Polaris, she worked in auditing, budget and cost accounting, and investment pension financial management at John Hancock Financial Services. She holds a BS in Finance from Siena College and an MBA from Babson College.
Megan Jahan is the accounting manager at Polaris Partners, which she joined in 2018 in the San Francisco office, working with the finance team on management company accounting. She previously spent over fourteen years in various accounting positions at VantagePoint Capital Partners. She holds a degree in Administrative Office Management from Renton College.
Michelle Pizzi joined Polaris Partners' Boston office in 2019 as a senior operations associate, where she supports the operations team's initiatives. She previously spent five years at The Fulham Group, managing the office and working with the finance department, and earlier held support roles at Mercer. She holds a BA in marketing with a minor in finance from Assumption College.
Molly Wilson joined Polaris in 2002 as executive assistant to co-founder and general partner Terry McGuire. Since 2010, she has co-founded and served as executive administrator for the Global Venture Capital Congress, organizing its annual meetings of venture capital associations worldwide. Her earlier career included executive assistant roles supporting leadership at EMC Corporation, Arch Wireless, Oak Industries, and Brandeis University, and she is a graduate of The Katharine Gibbs School in Boston.
Sean Thornton joined Polaris Partners' Boston office in 2022 as an office coordinator. Before Polaris, he worked as an assistant office manager at the Above the Rim sports complex.
Alicia Taylor is an Investment Director at Pembroke, where she joined in September 2022, focusing on new investments while supporting existing portfolio companies and their founding teams. She previously worked in Barclays Private Bank's ultra-high net worth investment team and spent three years at a boutique venture capital fund. She holds a first-class BSc in Management from Bristol University, the IMC Certificate, and has passed CFA Level One.
Emma Ward is Director of Talent at Pembroke, which she joined in March 2025, where she works with portfolio company leadership teams on Chair, NED, C-suite, and Board hiring. She previously served as European Managing Director of The Talent Business, an executive search firm in the brand and innovation space, and has 25+ years of management experience across brand consultancies and advertising agencies.
Founder mafia
7 people who came through Polaris Partners went on to found or lead other companies.
What they invest in
from 104 of 129 portfolio companiesBiotech ×62Healthtech ×44AI & Machine Learning ×31Medical Devices ×26SaaS ×16Deep Tech ×13Digital Health ×13Enterprise Software ×13
HQs:United States×98Belgium×1United Kingdom×1Ireland×1Netherlands×1Singapore×1
Investments · 129 tracked
founders shown can be your intro pathBy year:2026 · 52025 · 92024 · 72023 · 42022 · 132021 · 112020 · 122019 · 42018 · 62017 · 92016 · 112015 · 12117 dated
Alector develops therapies targeting neurodegenerative diseases including Alzheimer's, frontotemporal dementia, and Parkinson's disease through protein removal, replacement, and immune cell restoration.
AI & Machine LearningBiotechHealthtechLongevityMedical DevicesSan Francisco, US
Arnon Rosenthal(Ph.D.)inTillman Gerngross(Director)
BoardCarl Gordon(Director)
Board seatTerry McGuire· per SEC Form D
Co-investorsForesite CapitalGV (Google Ventures)Mission Bay CapitalMission BiocapitalMRL Ventures FundSV Health Investors
aTyr is a clinical-stage biotechnology company developing therapies derived from tRNA synthetase biology to treat fibrosis and inflammation, with its lead candidate efzofitimod in clinical trials for interstitial lung disease.
BiotechHealthtechMedical DevicesSan Diego, US
Paul Schimmel(Founder)John D. Mendlein(Executive Officer, Director)David Weiner(Executive Officer)inFrederic Chereau(Executive Officer)
BoardAkkaraju Srinivas(Non-Management Director)
Board seatAmir Nashat· per SEC Form D · $76.3M raise · filed Apr 2015
Co-investorsCardinal PartnersEcoR1 CapitalSofinnova VenturesViking GlobalDomain AssociatesDomain Partners+2 more
Camp4 Therapeutics develops antisense oligonucleotides targeting regulatory RNAs to increase gene expression and restore healthy protein levels for genetic diseases, with an initial focus on treating SYNGAP1-related developmental and epileptic encephalopathy.
BiotechCambridge, US
Richard Young(Director (Class II))Josh Mandel-Brehm(Chief Executive Officer and Director (Class III))in
BoardMICHAEL HIGGINS(Director)JORGE CONDE(Director)in
Board seatAmir Nashat· per SEC Form D · filed Jun 2022
Co-investors5AM VenturesAndreessen HorowitzLongwood Fund
Cardlytics operates a commerce media platform that uses card-linked purchase data to deliver targeted offers and closed-loop measurement for marketers and advertisers, and personalized rewards programs for banks and publishers.
AdTechFintechMarketing TechAtlanta, US
Scott Grimes(Founder)inLynne Laube(Founder)inKirk Somers(Executive Officer)inDavid Evans(Executive Officer)inAmit Gupta(Chief Executive Officer and Director)in
BoardJohn Klinck(Director)in
Board seatBryce Youngren· per SEC Form D · $11.9M raise · filed Jun 2017
Co-investorsBaroda VenturesCanaan PartnersKinetic Ventures, L.L.C.Next Coast VenturesSavano Capital PartnersDiscovery Capital+2 more
Cartesian Therapeutics is a clinical-stage biotechnology company developing mRNA-based cell therapies aimed at treating autoimmune diseases.
BiotechHealthtechWatertown, US
Metin Kurtoglu(Executive Officer)Omid Farokhzad(Director)Chris Jewell(Executive Officer)inCarsten Brunn(President, CEO & Chairman of the Board)inEmily English(Executive Officer)inBlaine Davis(Executive Officer)in
Board seatAmir Nashat· per SEC Form D · $70M raise · filed Jan 2020
Co-investorsK2 HealthVenturesMaryland TEDCOSchooner CapitalTEDCO+ND CapitalRUSNANO
Cyclerion is a biopharmaceutical company developing therapeutics for neuropsychiatric diseases, with a lead candidate (CYC-126) for treatment-resistant depression that pairs anesthetic agents with a personalized biofeedback-driven device.
BiotechDigital HealthMental HealthCambridge, US
William Huyett(Executive Officer)Mark G. Currie(Executive Officer)inRegina M. Graul(President and Chief Executive Officer)inOle Isacson(Director)Stephanie Lovell(Director)Marsha Fanucci(Director)
Board seatAmy SchulmanTerrance McGuire· per SEC Form D · $24.3M raise · filed Aug 2020
Co-investorsPappas CapitalAberdare VenturesEcoR1 CapitalInvus
Daré Bioscience is a female-led biotech company developing treatments for women's health conditions that are overlooked in the healthcare industry.
BiotechDigital HealthDirect to ConsumerFemTechHealthtechSan Diego, US
MarDee Haring-Layton(Chief Accounting Officer)inSabrina Martucci Johnson(Founder & Chief Executive Officer)Christopher D.T. Guiffre(Executive Officer, Director)Gregg Beloff(Executive Officer)Alejandra V. Carvajal(Executive Officer)Adrian Senderowicz(Executive Officer)
Board seatAlan Crane· per SEC Form D · $1 raise · filed Oct 2016
Co-investorsLilly VenturesVenrock
Fate Therapeutics develops investigational cellular immunotherapies to treat autoimmune diseases and cancer.
BiotechDigital HealthHealthtechMedical DevicesSan Diego, US
Christian Weyer(Executive Officer, Director)J. Scott Wolchko(Executive Officer)Daniel Shoemaker(Executive Officer)inBahram (Bob) Valamehr(President & Chief Executive Officer)in
BoardJohn Mendlein(Director)
Board seatAmir Nashat· per SEC Form D · $10.3M raise · filed Aug 2016
Co-investorsSanofi VenturesVenrockFidelity InvestmentsOVP Venture Partners
Fractyl develops therapies for obesity and type 2 diabetes, focusing on non-drug-based approaches rooted in understanding metabolic disease mechanisms.
BiotechHealthtechMedical DevicesLexington, US
Jay Caplan(Founder)inHarith Rajagopalan(Co-Founder and CEO)inLISA DAVIDSON(Executive Officer)inDiane Marcou(Executive Officer)in
BoardAllan Will(Director)inNimesh Shah(Director)in
Board seatAmy Schulman· per SEC Form D · $20.1M raise · filed Jan 2022
Co-investorsBessemer Venture PartnersCatalio Capital Management, LPEmergent Medical Partners, LLPGeneral CatalystMithril Capital ManagementDomain Associates+1 more
.png)
Invivyd is a biopharmaceutical company that develops antibody-based product candidates for the prevention and treatment of serious viral infectious diseases, combining viral surveillance and predictive modeling with antibody engineering.
BiotechHealthtechWaltham, US
Tillman U. Gerngross(Executive Officer, Director)Marc Elia(Founder)inLynn Connolly(Executive Officer)Eric Kimble(Executive Officer)inHalley Gilbert(Executive Officer)Rebecca Dabora(Executive Officer)in
Board seatTerry McGuireTerrance G. McGuire· per SEC Form D
Co-investorsBain Capital Life SciencesForesite CapitalGV (Google Ventures)MRL Ventures FundPremji InvestRA Capital+6 more
Pulmatrix develops inhaled dry-powder therapies using its proprietary iSPERSE technology, which uses small, dense, dispersible particles to deliver respiratory and non-respiratory drugs via the respiratory system.
BiotechDeep TechHealthtechMedical DevicesFramingham, US
Anand Varadan(Director)inRichard Batycky(Director)Peter Ludlum(Interim Chief Executive Officer)Hojabr Alimi(Executive Officer)Sameer Harish(Executive Officer)
BoardRichard Conley(Director)
Board seatTerrance McGuire· per SEC Form D · $3.7M raise · filed Dec 2018
Co-investors5AM VenturesALTITUDE LIFE SCIENCE VENTURESARCH Venture Partners
Scholar Rock is a biopharmaceutical company that develops therapies targeting growth factor proteins to treat serious diseases.
BiotechCambridge, US
Nagesh Mahanthappa(Executive Officer, Director)inTimothy Springer(Director)David Hallal(Chief Executive Officer, Chairman and Director)inAkshay Vaishnaw(President of Research & Development and Director)inR. Keith Woods(Chief Operating Officer)inVikas Sinha(Chief Financial Officer)in
Board seatAmir Nashat· per SEC Form D
Co-investorsAisling CapitalARCH Venture PartnersEcoR1 CapitalThe Kraft Group
Clinical-stage biopharmaceutical company focused on discovery and development of innovative medicines for serious diseases by targeting the Transforming Growth Factor Beta pathway.
BiotechCambridge, US
Nagesh Mahanthappa(Executive Officer, Director)Timothy Springer(Director)Yung H. Chyung(Executive Officer)Elan Z. Ezickson(Executive Officer)Akshay Vaishnaw(President of Research & Development and Director)R. Keith Woods(Chief Operating Officer)in
Board seatAmir Nashat· per SEC Form D · $47M raise · filed Jan 2018
Co-investorsSamsara BioCapitalARCH Venture PartnersEcoR1 Capital
Seer develops proteomics tools for large-scale protein analysis, including an assay, automation instrument, and analysis software for studying the proteome across human and non-human samples.
BiotechDeep TechHardwareHealthtechBoston, US
Omid Farokhzad(Founder)inPhilip Ma(Executive Officer)Shadi Aryanpour(Executive Officer)David Singer(Director)Omid Cameron Farokhzad(Founder)in
Board seatTerrance McGuire· per SEC Form D · $6M raise · filed Jan 2018
Co-investorsSoftBank Vision FundSolasta VenturesWingaMoonMaverick VenturesT. Rowe Price
Vaccinex is a clinical-stage biotechnology company developing pepinemab (VX15/2503), a humanized monoclonal antibody that blocks SEMA4D signaling, in trials for neurological disorders such as Huntington's and Alzheimer's disease and for solid tumors including breast cancer, melanoma, non-small cell lung cancer and head and neck cancer.
BiotechHealthtechMedical DevicesRochester, US
Maurice Zauderer, Ph.D.(President and CEO)Maurice Zauderer(Executive Officer, Director)inErnest S. Smith Ph.D.(Executive Officer)Jill Sanchez(Executive Officer)inErnest S. Smith(Executive Officer)inRaymond Watkins(Executive Officer)in
Board seatAlan Crane· per SEC Form D · $18.2M raise · filed Jul 2017
X4 Pharmaceuticals is a biopharmaceutical company developing medicines for people living with rare immune disorders, including chronic neutropenia.
BiotechBoston, US
Mary DiBiase(Executive Officer)inChristophe Arbet-Engels(Executive Officer)inDavid Kirske(Executive Officer)inJohn Volpone(Executive Officer)inMark Baldry(Executive Officer)Adam Craig(Executive Officer, Director)in
Board seatAmy SchulmanTerrance McGuire· per SEC Form D · $50.5M raise · filed May 2017
Co-investorsBain Capital Life SciencesLumira VenturesNew Enterprise Associates (NEA)Partners ResoluteThynk CapitalAdvent Life Sciences+1 more
Editas Medicine develops gene editing medicines using CRISPR/Cas9 and CRISPR/Cas12a technology to treat serious diseases including blood disorders, cardiovascular conditions, and cancer.
BiotechDeep TechMedical DevicesCambridge, US
Feng Zhang(Founder)inGeorge Church(Scientific Founder, Professor of Genetics, Harvard University and MIT)inKeith Joung(Scientific Founder, Professor of Pathology, Harvard Medical School)inDavid Liu(Scientific Founder, Professor of Chemistry and Chemical Biology, Harvard University)inKatrine Bosley(Executive Officer, Director)inVic Myer(Executive Officer)in
Co-investorsEcoR1 CapitalGV (Google Ventures)Sofinnova VenturesViking GlobalAtlas VentureDeerfield Management Company+2 more
Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLondon, US
Riley Ennis(Founder)inCharles Roberts(Founder)inGabriel Otte(Founder)inAdam Stone(Chief Executive Officer and Director)Michael Altman(Chief Business Officer and Director)Shmuel (Sam) M. Cohn(Chief Financial Officer)
Co-investorsRA CapitalAgent CapitalAME Cloud VenturesAndreessen HorowitzArtis VenturesAsset Management Company+15 more
Leyden Labs develops nasal sprays containing antibodies that target respiratory viruses such as influenza and COVID at the nasal mucosa to prevent initial infection and transmission.
BiotechDeep TechHealthtechLeiden, NL
Koenraad Wiedhaup(Founder & Chief Executive Officer)inRonald Brus(Founder & Chief Growth Officer)inJaap Goudsmit(Founding Scientist and Senior Advisor)inDinko Valerio(Founder and Chair of the Supervisory Board)inJintanat Ananworanich(Chief Medical Officer)inClarissa Koch(Chief Scientific Officer)in
Co-investorsClavystBioF-Prime CapitalGV (Google Ventures)Bluebird VenturesByers CapitalCasdin Capital+7 more
US agricultural biotech that discovered microbe-based crop protection products; its assets were sold to Certis Biologicals and Ginkgo Bioworks in 2024.
AgTechResearch Triangle Park, US
Scott Uknes(Manager)inEric Ward(Manager)Paul Schulze-Lefert(President)Michael Koziel(Vice President and Manager)
BoardThomas Dietz(Manager)Kristina Burow(Manager)in
Board seatAmir Nashat· per SEC Form D · $117.2M raise · filed Feb 2022
Co-investorsAliment CapitalBlue Horizon CorporationPontifax AgTechARCH Venture PartnersBill & Melinda Gates FoundationLeaps by Bayer+1 more
Ankyra Therapeutics is a biopharmaceutical company developing drugs, with a team that has collectively contributed to bringing seven drugs to global market approval.
BiotechDeep TechHealthtechMedical DevicesAustin, US
Tillman Gerngross(Executive Officer, Director)
Board seatTerrance McGuire· per SEC Form D · $14.5M raise · filed May 2020
Co-investorsGV (Google Ventures)Fidelity InvestmentsMithril Capital ManagementSands Capital VenturesSpring Mountain Capital
Seattle 'scientific wellness' startup that paired genetic, blood and microbiome testing with health coaching; closed in 2019.
HealthtechSeattle, US
Nathan Price(Director)Clayton Lewis(Executive Officer, Director)
BoardTim Kilgallon(Director)
Board seatTerry McGuire· per SEC Form D · $30M raise · filed Jun 2017
Co-investorsCorewell Health VenturesARCH Venture Partners
BiotechNewton, US
Katharine Yen(Executive Officer, Director)Kate Yen(Founder)inChristopher Guiffre(Executive Officer)
BoardAlon Lazarus(Director)Anna French(Director)in
Board seatAlexandra Cantley· per SEC Form D
Co-investorsDCVC (Data Collective)Qiming Venture Partners USAApollo Health VenturesBrightEdgeDCVC BioQiming Venture Partners
ByHeart is an infant formula company that manufactures science-driven baby formula with its own manufacturing process and supply chain.
ConsumerDirect to ConsumerFoodTechHealthtechNew York, US
Ron Belldegrun(Co-founder)inMia Funt(Founder)inGeorg Krause-Vilmar(Executive Officer)inNiall Mullane(Executive Officer)in
BoardHemi Zucker(Director)in
Board seatAmy Schulman· per SEC Form D
Co-investorsEvolution VC PartnersGaingelsOCV PartnersAF VenturesRed Sea VenturesVida Ventures
__Twitter.png)
Cirrus Therapeutics is a biotech developing gene and cell therapies based on ocular immunology to treat dry age-related macular degeneration (AMD), including an AAV gene therapy to restore the IRAK-M immune regulator and a next-generation retinal pigment epithelium (RPE) cell therapy for advanced geographic atrophy.
BiotechHealthtechLongevityCambridge, US
Ying Kai Chan(Co-founder & CEO)inAndrew Dick(Director, Promoter)
BoardKhoo Shih(Director)
Board seatAlexandra Cantley· per SEC Form D · $15.7M raise · filed Aug 2025
Co-investorsClavystBioLong GameZAKA VC
Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Alexander Nolte(Executive Officer)inDmitri Wiederschain(Executive Officer)in
BoardSakae Asanuma(Director)inBriggs Morrison(Executive Officer, Director, Promoter)inIrena Melnikova(Director)in
Board seatAlexandra Cantley· per SEC Form D · $80M raise · filed Sep 2025
Co-investorsLifelinkMPM BioImpactPfizer Venture InvestmentsBiotechnology Value FundMirae Asset Venture InvestmentPfizer Ventures+1 more
Dewpoint Therapeutics develops condensate-modulating drugs by using an integrated platform that maps, measures, and modulates biomolecular condensates to identify druggable targets and disease mechanisms.
AI & Machine LearningBiotechDeep TechBoston, US
Richard Young, Ph.D.(Director)inAnthony Hyman, Ph.D.(Director)Tony Hyman(Scientific Co-founder)Rick Young(Scientific Co-founder)Elisabeth Leiderman(Executive Officer)inIsaac Klein, M.D., Ph.D.(Executive Officer)
Board seatAmir Nashat· per SEC Form D
Co-investorsARCH Venture PartnersEcoR1 CapitalGeneral CatalystSamsara BioCapital6 Dimensions CapitalInnovation Endeavors+6 more
On-demand alcohol delivery platform providing consumers with a better way to shop for wine and spirits
Sherborn, US
Justin Robinson(Executive Officer)inNicholas Rellas(Executive Officer, Director)James Cory Rellas(Executive Officer)Joseph Grabmeier(Executive Officer)Jacqueline Flug(Executive Officer)Deborah Poole(Director)
Board seatPat Kinsel· per SEC Form D · $34.6M raise · filed Dec 2018
Co-investorsAvenir Growth CapitalEdmonton UnlimitedReynolds and Company Venture PartnersWinklevoss CapitalAvenirSuffolk Equity Partners+1 more
Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.
BiotechMedical DevicesSan Mateo, US
Ann Lee-Karlon(Executive Officer, Director)inMitchell Mutz(Executive Officer, Director)James Wells(Director)
BoardSamuel Bjork(Director)inSeiji Miyahara(Director)in
Board seatAlexandra Cantley· per SEC Form D
Co-investorsAvego BioScience CapitalGV (Google Ventures)Mission BiocapitalNovartis Venture FundRoche Venture FundSamsara BioCapital+4 more
Seattle biotech that developed FDY-5301 for cardiac and skeletal muscle injury; ceased operations in February 2026.
BiotechSeattle, US
Mark Roth(Executive Officer, Director, Promoter)Brian Blackman(Executive Officer)Simon Tulloch(Executive Officer)Stephen Hill(Executive Officer, Director)
BoardPaulina Hill(Director)inSteven Gillis(Executive Officer, Director, Promoter)in
Board seatTerrance McGuire· per SEC Form D · $102.8M raise · filed Nov 2022
Co-investorsARCH Venture PartnersOUP (Osage University Partners)
Cambridge, MA biotechnology company developing injectable synthetic biomarkers for noninvasive disease staging and treatment monitoring.
BiotechCambridge, US
Gabriel Kwong(Executive Officer)inSangeeta BhatiainRoopom Banerjee(Executive Officer)in
BoardTheresia Gouw(Director)inStan Lapidus(Director)in
Board seatAmy Schulman· per SEC Form D · $18M raise · filed Dec 2021
Co-investorsGreatPoint VenturesAcrew CapitalARCH Venture PartnersAspect VenturesCatalio Capital ManagementCRV (Charles River Ventures)+7 more
Iora Health was a primary care company focused on value-based care for Medicare-eligible seniors, operating clinics with a team-based model including health coaches.
Digital HealthHealthtechWellness & FitnessSan Francisco, US
RUSHIKA FERNANDOPULLE(Executive Officer, Director)inCHRISTOPHER J. MCKOWN(Executive Officer, Director)DAVID FIELDING(Executive Officer)ALEXANDER PACKARD(Executive Officer)inDAVID JUDGE(Executive Officer)
BoardSTEPHEN KNIGHT(Director)in
Board seatTerry McGuire· per SEC Form D
Co-investors.406 VenturesDag VenturesF-Prime CapitalFlare Capital PartnersGV (Google Ventures)Lifeforce Capital+10 more
Ironwood Pharmaceuticals is a gastrointestinal (GI) healthcare company focused on developing treatments for GI diseases.
BiotechDigital HealthHealthtechCambridge, US
PETER M. HECHT(Executive Officer, Director)inMARK G. CURRIE(Executive Officer)inHALLEY E. GIBLERT(Executive Officer)THOMAS GRANEY(Executive Officer)THOMAS A. MCCOURT(Executive Officer)in
Board seatTerrance G. Mcguire· per SEC Form D · $150M raise · filed Oct 2016
Co-investorsF-Prime CapitalMountain Group CapitalRidgeback CapitalVenrockMaverick Ventures
Jnana has developed RAPID, a next-generation chemoproteomics platform that enables rapid discovery of small molecule drugs targeting previously inaccessible disease targets by identifying novel binding sites on complex proteins.
AI & Machine LearningBiotechDeep TechAustin, US
Joanne Dove Kotz(Founder)inJoel Barrish(Chief Scientific Officer)Donald W. Nicholson(Director)Matthew Hammond(Director)Caroline Stark Beer(Chief Business Officer)Carlo Rizzuto(Director)
Board seatTerrance G. McGuire· per SEC Form D
Co-investorsAvalon BioVenturesBain Capital Life SciencesPfizer Venture InvestmentsRA CapitalPfizer VenturesVersant Ventures
Kallyope is a biotechnology company founded by neuroscientists that discovers and develops novel therapeutics targeting neural networks, with a lead candidate in pivotal studies for acute migraine treatment and metabolism programs approaching clinical studies.
BiotechHealthtechNew York City, US
Tom Maniatis(Founder)Nancy Thornberry(Executive Officer, Director)inKenneth Clark(Executive Officer)Charles Zuker(Founder)Richard Axel(Founder)
Board seatTerry McGuire· per SEC Form D · $44M raise · filed Oct 2016
Co-investorsDns CapitalIllumina VenturesLux CapitalThe Column GroupTwo Sigma Ventures
KSQ Therapeutics develops eTIL therapies—engineered tumor-infiltrating lymphocyte treatments for solid tumors—using its proprietary CRISPRomics platform to identify and target novel therapeutic candidates through genome-wide CRISPR/Cas9 functional genomic screens.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Tim Wang(Cofounder)JOHN TRZUPEK, PH.D.(TREASURER, SECRETARY & CHIEF FINANCIAL OFFICER)DAVID P. MEEKER, M.D.(PRESIDENT AND CHIEF EXECUTIVE OFFICER)inFRANK STEGMEIER, PH.D.(CHIEF SCIENTIFIC OFFICER)Qasim Rizvi(Chief Executive Officer)inJAMES GILBERT(Director)
Board seatAlan Crane· per SEC Form D
Co-investorsAlpha Wave GlobalARCH Venture PartnersFlagship PioneeringLAVLG Technology VenturesLilly Asia Ventures+3 more
San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.
BiotechSan Diego, US
Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)
BoardKristina Burow(Director)inRichard Heyman(Director)in
Board seatAmir Nashat· per SEC Form D · $37.8M raise · filed Nov 2016
Co-investorsage1EcoR1 CapitalLAVLifeSci Venture PartnersLilly Asia VenturesNew Enterprise Associates (NEA)+8 more
BiotechCambridge, US
Rick Lundberg(Executive Officer)George P. Vlasuk(Executive Officer, Director)in
BoardJean-Francois Formela(Director)inMarian Nakada(Director)inBrian Gallagher(Director)in
Board seatAlan Crane· per SEC Form D
Co-investorsage1Brace PharmaSanofi VenturesAtlas VentureSR One Capital Management
Noetik builds AI models to identify cancer patients most likely to respond to treatments and to discover new oncology drug targets.
AI & Machine LearningBiotechHealthtechSouth San Francisco, US
Jacob Rinaldi(Founder)inRonald Alfa(Executive Officer, Director, Promoter)Ron Alfa, MD, PhD(Co-Founder, CEO)inRon Alfa(Founder)Ron Alfa Jacob Rinaldi(Founder)
BoardJames Hardiman(Director)in
Board seatAmy Schulman· per SEC Form D
Co-investors11.2 CapitalBreakout LabsBreakout VenturesCatalio Capital Management, LPEPIC VENTURESIntermountain Health+6 more
Nomad Health operates an online marketplace that matches travel nurses and allied health clinicians with temporary healthcare jobs based on their profiles and preferences.
Digital HealthHealthtechMarketplacesNew York, US
Maxwell Laurans(Director)Alexi Nazem(Co-Founder & Board Member)inAlexander Nazem, MD(Founder)Max Laurens, MD(Founder)Ryan Grant, MD(Founder)inJustin Lambert(CEO)in
Board seatBrian Chee· per SEC Form D
Co-investorsAlleyCorpFirst Round CapitalIcon VenturesRRE Ventures.406 VenturesAdams Street Partners+1 more
Developing biologic therapies for autoimmune disorders; acquired by Merck for $1.85B in 2021.
BiotechCambridge, US
Jo Viney(Executive Officer)Rahul Kakkar(Executive Officer, Director)inAnthony Coyle(Executive Officer, Director)inChristopher Fuglesang(Director)Donald Frail(Director)Daniel Becker(Director)
Board seatAlan Crane· per SEC Form D
Co-investorsAccess BiotechnologyJDRF T1D FundMission BiocapitalRA CapitalSR One Capital ManagementVersant Ventures
Podimetrics offers a remote monitoring and care program for people with complex diabetes, centered on the SmartMat device that collects foot-health data to enable early intervention and prevent complications such as amputations.
Digital HealthHealthtechMedical DevicesSomerville, US
David Linders(Executive Officer, Director)inJonathan Bloom(Executive Officer, Director)
BoardAaron Sandoski(Director)in
Board seatAlexandra Cantley· per SEC Form D · $60M raise · filed Apr 2022
Co-investorsNorwich VenturesScientific Health DevelopmentSV Health InvestorsRock Health
Primmune Therapeutics develops PRTX007, an orally administered, systemically active TLR7 agonist that activates interferon-associated innate immune pathways for use in cancer immunotherapy.
BiotechHealthtechCarlsbad, US
James Appleman(SVP, R&D and CSO, Cofounder)Paulo Rangel(Chief Business Officer and Cofounder)inStephen Webber(Vice President, Medicinal Chemistry, and Cofounder)inCharles McDermott(President & CEO, Director)
BoardTodd J Harris(Director)in
Board seatAmir Nashat· per SEC Form D
Co-investorsBioBritBioRock VenturesSamsara BioCapitalBioqube VenturesOberland Capital
QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms.
BiotechDeep TechMedical DevicesCambridge, US
Kevin Eggan(Founder, QurAlis; Group Vice President, Head of Research and Early Development, BioMarin Pharmaceutical)inRoet(Co-founder)Woolf(Co-founder)Kasper Roet(Founder, Chief Executive Officer)inShafique Virani(Executive Officer)inJason Brown(Mr. Brown is the Chief Financial Officer of the Issuer.)in
Board seatAmy Schulman· per SEC Form D · $24.9M raise · filed Sep 2025
Co-investorsALS Investment FundDolby Family VenturesDroia VenturesInkefMC Healthcare VenturesMission Biocapital+8 more
Seismic Therapeutic is a clinical-stage biotechnology company that uses machine learning to discover and develop immunology therapies for autoimmune diseases.
AI & Machine LearningBiotechDeep TechMedical DevicesBoston, US
Timothy A. Springer(Scientific Advisor / Founder)Jo Viney, PhD(Founder, President and Chief Executive Officer)Alan Crane(Founder and Chairman of Seismic Therapeutic; Polaris Partners)inTim Springer, PhD(Founder of Seismic Therapeutic; Harvard Medical School and Boston Children's Hospital)Debora Marks, PhD(Founder)Andrew Kruse, PhD(Founder)
Board seatAlan Crane· per SEC Form D
Co-investorsBessemer Venture PartnersGaingelsGV (Google Ventures)Lightspeed Venture PartnersMana Ventures
Sofregen develops silk protein-based biomaterials and medical devices for soft tissue regeneration in aesthetic and surgical procedures.
BiotechHealthtechMedical DevicesNew MaterialsCambridge, US
Milan Kofol(Executive Officer)Doug Sheldon(Director)Anh Hoang(Executive Officer)Howard Weisman(Executive Officer, Director)
Board seatAmir Nashat· per SEC Form D · $9.7M raise · filed Sep 2017
Co-investorsAnzu Partners
Biotechnology company developing blood-based diagnostic tests for neurological disorders and early-stage cancer.
Cambridge, US
Board seatAlexandra Cantley· per SEC Form D
Co-investorsAlumni VenturesARCH Venture PartnersClavystBioS32
Syros Pharmaceuticals is a Massachusetts gene-control biotech developing small molecules that regulate disease gene expression.
BiotechCambridge, US
Nancy Simonian(CEO)Peter Wirth(Director)Mark Alles(Director)Philip Sharp(Director)Richard A. Young(Director)Sue Gail Eckhardt(Director)
Board seatAmir Nashat· per SEC Form D · $121.6M raise · filed Dec 2020
Co-investorsAisling CapitalARCH Venture PartnersQuan CapitalAlexandriaAlly Bridge GroupBain Capital+11 more
Tectonic is a clinical-stage biotechnology company developing therapeutic proteins and antibodies that target G-Protein Coupled Receptors (GPCRs) using a proprietary platform called GEODe™.
AI & Machine LearningBiotechMedical DevicesWatertown, US
Timothy A. Springer(Co-Founder)Andrew C. Kruse(Director)Alise Reicin(Executive Officer, Director)inDaniel Lochner(Executive Officer)Marc Schwabish(Executive Officer)inPeter McNamara(Executive Officer)in
Board seatTerry McGuire· per SEC Form D
Co-investorsEcoR1 CapitalVida VenturesAlly Bridge GroupClarus VenturesFarallon EquitiesSoleus Capital
Allstacks is an AI-agent platform that connects data from software development tools (Jira, GitHub, GitLab, Jenkins) to provide engineering teams and leaders with delivery metrics, risk alerts, and recommendations for planning, managing, and optimizing software creation.
AI & Machine LearningDeveloper ToolsEnterprise SoftwareRaleigh, US
Jeremy Freeman(Founder)inHersh Tapadia(Founder)inDarrell J. Freeman, Jr.(Executive Officer, Director)Scot Sherwood(Director)Alok Nandan(Director)
BoardAndrew Drylie(Director)in
Co-investorsAtlassian VenturesCompanyon VenturesCreativeCoFirst Rays Venture PartnersGutbrain VenturesHyperplane Venture Capital+9 more
Armorblox provides email security services, including customer support for handling security issues for its business customers.
CybersecurityEnterprise SoftwareSaaS
Anand Raghavan(Founder)Arjun Sambamoorthy(Founder)Chetan Anand(Founder)Dhananjay Sampath(Founder)
Co-investorsMango CapitalNext47Point72 VenturesS VenturesTau VenturesA.Capital Ventures+3 more
August Bioservices is a contract research, development, and manufacturing organization (CDMO) specializing in sterile injectables, offering end-to-end services from development to commercial manufacturing.
Advanced ManufacturingBiotechHealthtechMedical DevicesNew Brunswick, US
Jenn Adams(CEO)
Co-investorsOak HC/FT
Repligen provides bioprocessing technologies—including process intensification, tangential flow filtration, chromatography, process analytics, and single-use fluid management—for upstream and downstream biopharmaceutical workflows.
BiotechHardwareMedical DevicesLebanon, US
Tillman Gerngross(Director)Errik Anderson(Director)inWarren Kett(Executive Officer)Jon Sheller(Executive Officer)Kevin Issett(Executive Officer, Director)Kevin Isett(Executive Officer, Director)
Co-investorsOrbiMedSV Health InvestorsBorealis VenturesMithril Capital ManagementNeomed ManagementSands Capital Ventures+1 more
B12 offers an AI-powered website builder that generates a complete first draft of a website, online store, portfolio, blog, or web app from a text prompt, which users can then refine via an AI agent or visual editor.
AI & Machine LearningMarketing TechSaaS
Nitesh Banta(Founder)inAdam Marcus(Founder)in
Co-investorsFrancisco PartnersLightbankLux CapitalSuffolk Equity PartnersBrand Capital InternationalFounder Collective+6 more
Baxter Planning provides software and services for service supply chain management, serving enterprises managing complex operational logistics and supplier networks.
AI & Machine LearningEnterprise SoftwareLogistics & Supply ChainSaaS
Anton Chilton(Chief Executive Officer)in
Co-investorsGolub GrowthMarlin Equity Partners
Cohere Health provides a platform aimed at aligning the interests of patients, physicians, and health plans to support care decisions and improve member outcomes.
AI & Machine LearningDigital HealthEnterprise SoftwareHealthtechSaaSBoston, US
Siva Namasivayam(Executive Officer, Director)inRobert Shepardson(Executive Officer)inKristen Carucci(Executive Officer)inDuncan Reese(Executive Officer)
BoardDavid Barrett(Director)Amir Debourou(Director)
Co-investorsCota CapitalFlare Capital PartnersLongitude CapitalDeerfield Management CompanyDefine VenturesTemasek
Dyno Therapeutics develops artificial intelligence-powered genetic technologies for gene therapy, specifically engineering adeno-associated virus (AAV) capsids to improve gene delivery for treating genetic diseases.
AI & Machine LearningBiotechWatertown, US
Eric Kelsic(Founder)inSam Sinai(Founder)inAdrian Veres(Founder)inGeorge Church(Scientific Cofounder, SAB)inTomas Bjorklund(Scientific Co-founder, SAB)inAlan Crane(Founder)in
Co-investorsAndreessen HorowitzCRV (Charles River Ventures)GENERAL INCEPTIONGV (Google Ventures)Lux CapitalObvious Ventures+2 more
Egnyte provides software for protecting and managing business-critical content across organizations of all sizes.
AI & Machine LearningCloud ComputingCybersecurityEnterprise Software
Vineet Jain(Chief Executive Officer)inAmrit Jassal(Founder)in
Co-investorsTA AssociatesGI PartnersFloodgateGolub GrowthGV (Google Ventures)Menlo Ventures+3 more
Engine Bio presents itself as a company working on new cancer medicines.
BiotechSingapore, SG
Daphne Teo(Founder)in
Co-investorsClavystBioNSG VenturesWI Harper Group
One Health operates a clinical trial platform using canine cancer data to accelerate and de-risk human oncology drug development.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesSan Francisco, US
Christina Lopes(Founder)inBenjamin Lewis(COO)inchristina lopesinPedro Carrasco(Chief of Staff)Christi Miller(Head of Operations)
Co-investorsAndreessen HorowitzaVentureCivilization Ventures Management, LlcGaingelsGlobal BrainIKJ Capital+16 more
FIRE1 develops NORM, an implantable sensor placed in the inferior vena cava to directly measure fluid volume in heart failure patients, paired with a self-management platform to help patients engage with their own care.
Digital HealthHardwareMedical DevicesDublin, IE
Co-investorsAndera PartnersGimvIreland Strategic Investment FundLightstone VenturesLongitude CapitalNew Enterprise Associates (NEA)+5 more
FloQast provides reconciliation management and workflow automation software for accounting teams, designed by accountants to streamline financial processes and improve productivity.
AI & Machine LearningConsumerEnterprise SoftwareFintechFoodTechSaaS
Mike Whitmire(Founder)inChris Sluty(Founder)inKushal Malde(Head of Financial Control)inCullen Zandstra(Founder)Michael Whitmire(Founder)
Co-investorsAmplify.LAICONIQInsight PartnersLeft Lane CapitalNewView CapitalNorwest Venture Partners+9 more
.png)
FOLX is a digital healthcare platform designed for LGBTQIA+ adults, providing inclusive and affirming medical care.
Digital HealthHealthtechBoston, US
A.G. Breitenstein(Founder)inLena Ballantine(Executive Officer)inLiana M Guzman Weis(Executive Officer, Director)
BoardLynne Chou O'Keefe(Director)inMorgan Cheatham(Director)inLee Shapiro(Director)in
Co-investors7wire VenturesBessemer Venture PartnersCorewell Health VenturesDefine VenturesHabitat PartnersSeae Ventures+2 more
Fridge lets users create temporary, private social spaces for groups to share photos, videos, and messages without relying on mainstream social networks.
ConsumerSocialSan Francisco, US
Austin Chang(CEO)inAlex Chung(Founder)
Co-investorsY CombinatorBessemer Venture PartnersKapor CapitalMantis CapitalRaptor Group
AI & Machine LearningEnterprise SoftwareHR TechSaaSNew York, US
Joe Essenfeld(Executive Officer, Director)in
BoardNilanjana Bhowmik(Director)inRoss Goldstein(Director)inPeter Flint(Director)R. Douglas Higgins(Director)Jim Baum(Director)
Co-investorsConvergeLerer HippeauMontage CapitalRunway Growth CapitalSapphire VenturesDFJ+3 more
Vertically-integrated machine learning platform for healthcare powering transition to value-based care with predictive analytics.
Co-investorsMindset VentureOUP (Osage University Partners)
BiotechBoston, US
Nagesh Mahanthappa, Ph.D.(Director)Luba Greenwood(Director)in
BoardAmir Nashat, Ph.D.(Treasurer and Secretary)Susan Langer(President)Thomas J. Cahill(Director)
Co-investors5AM VenturesCathay HealthNewpath Partners
Livara Health provides personalized musculoskeletal (MSK) care through a network of clinicians, using customized care plans to reduce MSK-related costs and improve patient outcomes.
Digital HealthHealthtech
Co-investorsA1 Health VenturesMartin Ventures
Lob provides software and hardware infrastructure for automating, personalizing, and tracking direct mail campaigns at scale.
Enterprise SoftwareLogistics & Supply ChainMarketing TechSaaSNew York City, US
Harry Zhang(Founder)inLeore Avidar(Founder)inEduardo Browne(Executive Officer)Donnell Vanker(Executive Officer)Ryan Ferrier(Chief Executive Officer)inAnna Donavan
Co-investorsFirst Round CapitalFloodgateFrontline VenturesFundersClubInitialized CapitalSaints Capital+22 more
Localytics is an AI implementation firm that builds, integrates, and operates marketing AI systems for enterprise consumer brands.
AI & Machine LearningEnterprise SoftwareMarketing TechSaaSBoston, US
John Dobrowolski(CEO)inDerick Thompson(VP of Operations)inJuan Yrigoyen(Head of Product)inJoey Rahman(Head of Engineering)inCarl Jones(CTO)
Co-investorsBantam GroupFoundation CapitalLaunchCapitalMI VenturesSapphire VenturesTechstars+2 more
AI & Machine LearningCloud ComputingCybersecurityData & InfrastructureEnterprise Software
Trevor Parsons(Founder)Viliam Holub(Founder)
Co-investorsFrontline VenturesRRE VenturesEnterprise IrelandFloodgate
Matter develops a consumer iOS app that helps users track positive emotions and brain activity to improve subjective well-being.
AI & Machine LearningConsumerHealthtechMental HealthWellness & Fitness
Axel Bouchon(Founder)inBen Goldhirsh(Co-founder)inChris Shiflett(Co-founder)in
Co-investorsARCH Venture PartnersCollaborative FundExor Ventures
Montis Biosciences develops anti-C1q antibodies that target both the complement and myeloid axes to treat neuroinflammatory, autoimmune, neurodegenerative and ophthalmic diseases, with a lead program in Guillain-Barré syndrome and a second CD93 program in lung squamous cell carcinoma.
BiotechHealthtechLeuven, BE
Federico Grossi(Clinical Advisor & Acting CMO)
Co-investorsDroia VenturesPfizer VenturesVIBPfizer Venture Investments
OM1 develops AI-powered analytics and data infrastructure for healthcare organizations to measure patient outcomes, predict health trajectories, and accelerate medical research using real-world clinical data.
AI & Machine LearningData & InfrastructureHealthtechMedical DevicesBoston, US
Richard Gliklich, MD(Founder)Richard E. Gliklich(Executive Officer, Director)Richard Gliklich(Founder)
BoardRory O'Driscoll(Director)inLarry Bohn(Director)David Barrett(Director)
Co-investors7wire VenturesBreyer CapitalCorewell Health VenturesGeneral CatalystM33 GrowthScale Venture Partners
Preply is a language learning platform that serves corporate employees through its B2B offering Preply Business, enabling companies to provide language education to their workforce.
AI & Machine LearningB2B MarketplacesEdTechHR TechMarketplacesSaaSBrighton, US
Dmytro Voloshyn(Co-founder and CTO)inKyrylo Bigay(Executive Officer, Director)Kirill Bigai(Co-founder and CEO)inSergey Lukyanov(Former Co-Founder)inCharlie Wickers(Executive Officer)inBoris Shakhnovich(Executive Officer)
Co-investorsAcurio VenturesCogito Capital PartnersDigital Future Investments LtdEducapitalEvli Growth PartnersFlashpoint Venture Capital+18 more
Prolaera provides a learning management platform for CPA firms that automates Continuing Professional Education (CPE) tracking, offers a built-in course library, and lets firms create and deliver self-study, webinar, and live courses.
EdTechFuture of WorkHR TechSaaS
Evan HinerinGary KnoppinJassen Bowmanin
Co-investors500 Global9Mile Labs
Qstream offers a microlearning platform with AI tools that turn existing content into short, scenario-based training courses.
AI & Machine LearningEdTechSaaSBurlington, US
Duncan Lennox(Executive Officer, Director, Promoter)inBranch Price Kerfoot(Director)
BoardHambleton Lord(Director)inShay Garvey(Director)inGaye Bok(Director)Harold Copperman(Director)
Co-investorsDelta PartnersExcel Venture ManagementLaunchpad Venture GroupEnterprise IrelandBantam GroupFrontline Ventures
ReadyForZero built a web and mobile platform that helped people create debt repayment plans, process payments, monitor credit scores, and track progress toward reducing their debt obligations.
FintechLos Angeles, US
Rod Ebrahimi(CEO)inIgnacio Thayer(CTO)inChris Granger(Software Engineer)inKevin Yu(Head of Content Marketing)inLoren Baxter(Lead Designer)in
Co-investors500 GlobalY CombinatorCiti Ventures
Recurly provides a subscription management platform that automates recurring billing, payments recovery, churn reduction, and revenue recognition for digital commerce and subscription businesses.
E-commerceFintechSaaSSan Francisco, US
Dan Burkhart(Founder)inIsaac Hall(Founder)in
BoardDavid Barrett(Director)
Co-investors500 GlobalAccel-KKREvolution VC PartnersF-Prime CapitalFreestyle CapitalHeadline
Satellite Bio develops an off-the-shelf cell therapy that delivers functional liver cells (hepatocytes) into the body, where they engraft to restore liver function.
BiotechHealthtechCambridge, US
Christopher Chen(Director, Promoter)inThomas Lowery(Executive Officer)
BoardEllie McGuire(Director)Ling Wong(Director)Sujata Bhatia(Director)William Young(Director)
Co-investorsAlumni VenturesaMoonCatalio Capital Management, LPLightspeed Venture PartnersHighbury HoldingsS32
Simon AI offers an agentic marketing platform for lifecycle marketers to plan and launch personalized campaigns through a conversational, goal-based AI workflow.
AI & Machine LearningMarketing TechSaaSNew York City, US
Jason Davis(Founder)
Co-investorsF-Prime Capital.406 Ventures
Simon AI provides customer data and personalization tools to marketing teams for driving one-to-one customer messaging across touchpoints.
AI & Machine LearningData & InfrastructureMarketing TechSaaSBrooklyn, US
Jason Davis(Founder)inMatt Walker(Founder)inJoshua Neckes(Founder)
Co-investors.406 VenturesCommerce VenturesBoxGroupEight Roads VenturesSlow Ventures
SimplyInsured operates a 100% online platform for small business owners to purchase and manage health insurance in the United States.
HealthtechInsurTechSaaSSan Francisco, US
Vivek Shah(Founder)inCraig Brott(Software Engineer)George HuoCharles Szymanski(Software Engineer)Gillian Barrett(Recruiter)David Bai(Head of Engineering)
Co-investorsY CombinatorBessemer Venture PartnersCorazon CapitalLevel EquityNew York Life VenturesAgrolimen Ventures+2 more
Customer experience management software combining content, commerce, and data into one connected platform for context marketing.
AI & Machine LearningEnterprise SoftwareMarketing Tech
Eric StineinJakob Christensen(Founder)Michael Seifert(Founder)Peter Christensen(Founder)Thomas Albert(Founder)
Co-investorsFrontline VenturesTola CapitalEQTTCVTechnology Crossover Ventures
Sonrai Security provides a cloud permissions management platform that enforces least privilege access across cloud identities and services.
AI & Machine LearningCloud ComputingCybersecurityEnterprise SoftwareNew York, US
Brendan Hannigan(Founder)inSandy Bird(Founder)inWilliam Bird(Executive Officer, Director)
BoardDave Barrett(Director)Venky Ganesan(Director)inAlex Doll(Director)in
Co-investorsaVentureMenlo VenturesTen Eleven
Soufflé Therapeutics develops nucleic acid medicines that precisely target and deliver genetic therapeutics to specific cell types to treat disease.
AI & Machine LearningBiotechDeep TechWatertown, US
Victor Kotelianski(Founder)Daniel Anderson(Founder and Director)Robert Langer(Founder)Marino Zerial(Founder)Brad Pentelute(Founder)Amir Nashat, ScD(Founder, Director and CEO)
Co-investorsLeaps by BayerBessemer Venture PartnersSafar PartnersVida Ventures
Stensul is a no-code marketing creation platform that lets enterprise marketing teams build emails and other content through governed, collaborative workflows with built-in guardrails.
Enterprise SoftwareMarketing TechSaaSNew York, US
Noah Dinkin(Founder)in
Co-investors515 VenturesFirst Round CapitalJavelin Venture PartnersSageview CapitalUS Venture PartnersAlchemist Accelerator+7 more
A company offering regenerative and aesthetic medical products for facial, breast, and body treatments across all stages of life.
HealthtechMedical DevicesSan Diego, US
Nicholas L. Teti, Jr.(Executive Officer, Director)Joseph A. Newcomb(Executive Officer)Stewart M. Brown(Executive Officer)in
BoardClarke B. Futch(Director)Paul J. Hadden(Director)Todd C. Davis(Director)
Co-investorsBioBritEssex Woodlands Healthcare PartnersWestern Technology InvestmentHEALTHCARE ROYALTY PARTNERS
Swiftly provides a data platform for public transit agencies to track vehicle locations, generate real-time passenger information and arrival predictions, and analyze historical operations data.
Data & InfrastructureGovTechMobility & Transportation
Co-investorsBuilders + BackersJMI EquityPlug and Play VenturesRenewal FundsSHAKTIVia ID+3 more
HealthtechLexington, US
Michael Cima, Ph.D.(Director)Rahul Dhanda(Senior Vice President, Corporate Development)inJohn McDonough(Chief Executive Officer)inTom Lowery, Ph.D.(Chief Scientific Officer)Michael Gibbs, Esq.(Vice President and General Counsel)Joanne Spadoro, Ph.D.(Chief Operating Officer)in
Co-investorsAisling CapitalAPERTURE Venture PartnersIn-Q-TelArcus VenturesFlagship VenturesFlybridge Capital Partners+2 more
Tausight provides Active Containment technology that stops ransomware attacks in real-time by monitoring encryption and preventing operational disruption, eliminating downtime during attacks.
Cybersecurity
David Ting(Founder)in
Co-investorsFlare Capital Partners.406 Ventures
Tavo Biotherapeutics develops novel treatments for glaucoma and retinal diseases, focusing on disease-modifying therapies that target the root biological mechanisms of vision loss.
BiotechHealthtechMedical Devices
Co-investorsPureos Bioventures
Astoria, US
Demetrius Michael Karagas(Executive Officer, Director)Steven Gutentag(Founder)inDemetri Karagas(Founder)
BoardRebecca Kaden(Director)in
Co-investorsAlpha PartnersAlumni VenturesComcast VenturesConnetic VenturesCVS Health VenturesEvolution VC Partners+19 more
TRexBio develops biologic medicines targeting inflammation in autoimmune and inflammatory diseases by decoding human tissue biology.
AI & Machine LearningBiotechDeep TechHealthtech
Johnston Erwin(Chief Executive Officer)Ali Zarrin(Chief Scientific Officer)
Co-investorsAvego BioScience CapitalDelos CapitalDementia Discovery FundPfizer Venture InvestmentsSV Health InvestorsAgent Capital
Vico Therapeutics develops targeted genetic medicines for neurological disorders, with a focus on antisense oligonucleotide therapies designed to address the underlying genetic causes of diseases like Huntington's disease and spinocerebellar ataxias.
AI & Machine LearningBiotechDeep TechHealthtechMedical Devices
Luc Dochez(Chair and Founder)inJosh Mandel-Brehm(Co-Founder)in
Co-investorsDroia VenturesKurma PartnersPureos BioventuresEQT Life SciencesSeroba Life SciencesEurazeo+1 more
Volastra Therapeutics is a drug discovery and development company working on novel cancer therapies.
BiotechHealthtechNew York, US
Samuel Bakhoum(Co-Founder & Chief Scientific Officer)inLewis Cantley(Founder and Chair of Scientific Advisory Committee)Olivier Elemento(Founder and Scientific Advisor)David P. Southwell(Chief Executive Officer)in
BoardRobert Mittendorff(Director)inJill Goldstein(Director)in
Co-investorsDroia VenturesARCH Venture PartnersB Capital GroupB4 CapitalVida VenturesCatalio Capital Management
.jpeg){kind=logo}
Zag Bio develops thymus-targeted bifunctional antibodies designed to induce central tolerance for treating autoimmune diseases.
BiotechDeep TechHealthtechMedical DevicesCambridge, US
Alan Crane(Founder)Diane Mathis(Founder)Joanne Lim(Co-founder)Dr. Diane Mathis(Founder)Jo Viney(Founder)John Kulman(Founder)
Co-investorsLightspeed Venture PartnersMission BiocapitalPear VCSanofi VenturesThe Engine Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
1366 Technologies480 BiomedicalAmagma, Inc.Athletes' PerformanceBe Me HealthBlue Rabbit VenturesCardurion Pharmaceuticals, Inc.Freenome HoldingsIcelandic ProvisionsLyndraMicrochips BiotechMorphic Holding, Inc.Pulmatrix OperatingSequelaeSeventh Sense BiosystemsTRex Holdings Inc.XTuit PharmaceuticalsAnkyraApnex MedicalArsanisBlackThorn TherapeuticsFirst OpinionJibJab Bros StudiosKnowledge FactorLarkspur BiosciencesLiving ProofSea PharmaceuticalsTessa TherapeuticsTome BiosciencesTropicU S HealthVestYourBio Health
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 34
20 IPOs · 14 acquisitions · showing 26AlectorNASDAQ: ALECaTYR PHARMANASDAQ: ATYRCamp4 Therapeutics CorpNASDAQ: CAMPCardlyticsNASDAQ: CDLXCartesian Therapeutics (NASDAQ: RNAC)NASDAQ: RNACCyclerion TherapeuticsNASDAQ: CYCNDare BioscienceNASDAQ: DAREFate TherapeuticsNASDAQ: FATEFractylNASDAQ: GUTSInvivydNASDAQ: IVVDPulmatrixNASDAQ: PULMScholar RockNASDAQ: SRRKScholar Rock Holding Corp, Inc.NASDAQ: SRRKSeerNASDAQ: SEERVaccinexOTC: VCNXX4 PharmaNASDAQ: XFOREditas MedicineNASDAQ: EDITFreenomeNASDAQ: FRNMIora Healthacq. by One MedicalJnana Therapeuticsacq. by OtsukaPandion Therapeuticsacq. by MerckArmorbloxacq. by CiscoAvitideacq. by RepligenJibeacq. by iCIMSLocalyticsacq. by UplandLogEntriesacq. by Rapid7
Portfolio news
latest coverage across their companiesInvivyd · investors.invivyd.com · Sep 1, 2026
Recurly · fintech.global · Aug 21, 2026
Seer · aol.com · Aug 18, 2026
KenSci · chiefhealthcareexecutive.com · Aug 17, 2026
Ironwood Pharmaceuticals · finance.yahoo.com · Aug 6, 2026
Leyden Labs · techfundingnews.com · Jun 25, 2026
Fund performance · per public LP disclosures · 3
as of Jun 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| Polaris Growth FundLPs: Los Angeles City Employees' Retirement System, Pension Reserves Investment Management Board | 2018 | — | 36.8% | 2.86x | 0.57x |
| Polaris Partners VIIILPs: Hawaii Employees' Retirement System, Los Angeles City Employees' Retirement System | 2017 | — | 15.8% | 2.08x | 1.10x |
| Polaris Partners VIILPs: Los Angeles City Employees' Retirement System, Hawaii Employees' Retirement System | 2014 | — | 8.5% | 1.88x | 0.68x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Public market activity · per SEC filings
what is this? ⓘDisclosed stake · filed Feb 2024
Disclosed stake · filed Feb 2022
Disclosed stake · filed Feb 2021
Disclosed stake · filed Feb 2020
Disclosed stake · filed Feb 2019
Disclosed stake · filed Jul 2016
9 insider ownership filings (Forms 3/4/5)
at Camp4 Therapeutics Corp (CAMP)
From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.
Frequently asked questions
- How many investments has Polaris Partners made?
- Polaris Partners has 129 tracked investments, 34 of which have exited, including 15 dated in the last 24 months.
- What stage does Polaris Partners invest at?
- Polaris Partners invests at the Seed, Series A, Series B, Series C, Growth stages.
- What is Polaris Partners's typical check size?
- Polaris Partners typically writes checks of $500K – $5M.
- What sectors does Polaris Partners focus on?
- Polaris Partners focuses on Biotech, Consumer, Digital Health, Healthtech.
- Where is Polaris Partners located?
- Polaris Partners is headquartered in Boston, US.
Media · Podcasts & interviews
featuring the teamTech Investing Mastermind: Terry McGuire- Co-founder of Polaris Partners & Chairman Emeritus of NVCA
Grace Gong · Terry McGuire
Fireside Chat with Robert Langer (KI) and Terry McGuire (Polaris Partners)
KochInstituteMIT · Terry McGuire
Co-investors · 135
ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.
General Catalyst is a global venture capital and investment firm backing founders across stages and industries, with a notable focus on AI, healthcare transformation, defense, and space.
Bessemer Venture Partners is a global venture capital firm that partners with entrepreneurs across enterprise, consumer, and healthcare sectors from early stages through growth.
F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.
RA Capital Management is a healthcare and planetary health investment firm that founds, funds, and scales companies using scientific diligence, multi-stage capital, and hands-on operational support.
SV Health Investors is a global private equity and venture capital platform dedicated to healthcare, running specialized funds across biotechnology (including dementia), healthcare growth equity, and medtech.
.406 Ventures is an early-stage venture capital firm that partners with founders building companies in healthcare, data and AI, and cybersecurity.
Mission BioCapital provides early-stage capital and shared lab space to life science entrepreneurs, supporting companies from idea through clinic and exit.
Atlas Venture is a biotechnology-focused venture firm that creates and builds breakthrough life science companies, backing entrepreneurs to translate scientific research into new medicines.
5AM Ventures is a life science venture capital firm founded in 2002 that funds and builds next-generation life sciences companies, focusing on biopharmaceuticals, drug delivery technologies, and life science instruments.
▶123 more co-investors
Sanofi VenturesMithril Capital ManagementFlagship PioneeringPfizer Venture InvestmentsVida VenturesCatalio Capital Management, LPLightspeed Venture PartnersTechstarsDCVC (Data Collective)CRV (Charles River Ventures)Sapphire VenturesFloodgateVenrockFlare Capital PartnersS32Aisling CapitalBorealis VenturesInsight PartnersMenlo VenturesRRE VenturesSoftBank Vision FundOrbiMedLocus VenturesEQT Life SciencesVersant VenturesSR One Capital ManagementJohnson & Johnson Innovation – JJDCMPM BioImpactDomain AssociatesVivo CapitalDefine VenturesQiming Venture PartnersaMoonHealthQuest CapitalKhosla VenturesFounder CollectiveUncork CapitalFoundation CapitalB Capital GroupNorwest Venture PartnersCanaan PartnersOak HC/FTFreestyle CapitalHeadlineScale Venture PartnersObvious VenturesMeritech Capital PartnersNext47MaveronLowercase CapitalUS Venture PartnersUnusual VenturesLeft Lane CapitalZetta Venture PartnersWildcat Venture PartnersJavelin Venture PartnersOwl VenturesHoxton VenturesScrum VenturesAmasiaHighbury HoldingsArtis VenturesTen ElevenGreatPoint VenturesAutotech VenturesMarket One CapitalDigitalis VenturesKurma PartnersAdvent Life SciencesRiverVest Venture PartnersApollo Health Ventures+ND CapitalVertex Ventures HCBroadview VenturesGreylock PartnersBenchmarkFelicis VenturesFJ LabsCoatue ManagementEniac VenturesGoat CapitalNextView VenturesBling CapitalC2 InvestmentsStellar CapitalResolute VenturesStride VCBonfire Ventures01 AdvisorsHarrison MetalBAM VenturesAccompliceVillage Global75 & SunnyBetter Tomorrow VenturesStandard CapitalNextGen Venture PartnersSaga Ventures23andMeMoxxie VenturesBreakthrough Energy VenturesHighland Capital Partnersfoobar.vcVitalStage VenturesBIOSPRING PARTNERSSamsung NextStrata Capital PartnersForbionPillar VCAscension VenturesAsset Management VenturesAbingworthbyFoundersRepublic Capital (ex Republic Labs)Vinyl CapitalAlta PartnersCofounders CapitalMedical Excellence CapitalPontifax Venture CapitalAvoro Capital AdvisorsACORN BIOVENTURESAltitude Ventures Management, Llc3TS Capital Partners
Firms observed investing alongside Polaris Partners, from public investor directories. Shared companies are the overlap with Polaris Partners's recorded portfolio.
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Bessemer Venture Partners is a global venture capital firm that partners with entrepreneurs across enterprise, consumer, and healthcare sectors from early stages through growth.
General Catalyst is a global venture capital and investment firm backing founders across stages and industries, with a notable focus on AI, healthcare transformation, defense, and space.
Alkemi Growth Capital is an India-focused early-stage growth fund investing exclusively in scalable healthcare and wellness companies with validated product-market fit and a clear pathway to institutional scale.